[go: up one dir, main page]

BR0214716A - Contraceptivos para prevenção de gravidez e diminuição de sintomatologia pré-menstrual - Google Patents

Contraceptivos para prevenção de gravidez e diminuição de sintomatologia pré-menstrual

Info

Publication number
BR0214716A
BR0214716A BR0214716-5A BR0214716A BR0214716A BR 0214716 A BR0214716 A BR 0214716A BR 0214716 A BR0214716 A BR 0214716A BR 0214716 A BR0214716 A BR 0214716A
Authority
BR
Brazil
Prior art keywords
decrease
contraceptives
prevent pregnancy
premenstrual symptoms
pregnancy
Prior art date
Application number
BR0214716-5A
Other languages
English (en)
Other versions
BRPI0214716B8 (pt
BRPI0214716B1 (pt
Inventor
Robert G Bell
Carole Benmaimon
Beata Iskold
Original Assignee
Barr Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23313290&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0214716(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Barr Lab Inc filed Critical Barr Lab Inc
Publication of BR0214716A publication Critical patent/BR0214716A/pt
Publication of BRPI0214716B1 publication Critical patent/BRPI0214716B1/pt
Publication of BRPI0214716B8 publication Critical patent/BRPI0214716B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"CONTRACEPTIVOS ORAIS PARA PREVENçãO DE GRAVIDEZ E DIMINUIçãO DE SINTOMATOLOGIA PRé-MENSTRUAL". A presente invenção refere-se a um método de evitar gravidez e tratar PMS incluindo PMDD. Mais particularmente, a invenção refere-se a um método, que envolve a administração de um de vários regimes de contraceptivo oral em combinação, em combinação com um antidepressor e um kit contendo o mesmo.
BR0214716A 2001-12-05 2002-12-04 kit, preparos, e uso de estrogênio e progestina na fabricação de um medicamento para uso na prevenção de gravidez BRPI0214716B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33580701P 2001-12-05 2001-12-05
US60/335.807 2001-12-05
PCT/US2002/038602 WO2003049744A1 (en) 2001-12-05 2002-12-04 Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology

Publications (3)

Publication Number Publication Date
BR0214716A true BR0214716A (pt) 2004-12-14
BRPI0214716B1 BRPI0214716B1 (pt) 2018-10-02
BRPI0214716B8 BRPI0214716B8 (pt) 2021-05-25

Family

ID=23313290

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0214716A BRPI0214716B8 (pt) 2001-12-05 2002-12-04 kit, preparos, e uso de estrogênio e progestina na fabricação de um medicamento para uso na prevenção de gravidez

Country Status (23)

Country Link
US (5) US7320969B2 (pt)
EP (3) EP1453521B1 (pt)
JP (3) JP2005516913A (pt)
CN (2) CN101757628A (pt)
AU (2) AU2002348272B2 (pt)
BG (1) BG108736A (pt)
BR (1) BRPI0214716B8 (pt)
CA (2) CA2655959C (pt)
DK (1) DK1453521T3 (pt)
ES (2) ES2428118T3 (pt)
FR (1) FR15C0050I2 (pt)
HK (2) HK1076716A1 (pt)
HU (2) HU230759B1 (pt)
IL (3) IL162182A0 (pt)
LU (1) LU93156I2 (pt)
MX (1) MXPA04005445A (pt)
NZ (4) NZ555299A (pt)
PL (1) PL213122B1 (pt)
PT (1) PT1453521E (pt)
RU (1) RU2351339C2 (pt)
SI (1) SI1453521T1 (pt)
WO (1) WO2003049744A1 (pt)
ZA (1) ZA200404249B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5898032A (en) 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
PT1453521E (pt) 2001-12-05 2013-10-08 Teva Womens Health Inc Contracetivos orais para prevenir a gravidez e diminuir a sintomatologia pré-menstrual
US7005138B2 (en) * 2001-12-21 2006-02-28 Duramed Pharmaceuticals, Inc. Method of systematically delivering SSRIs
US20090163454A1 (en) * 2003-05-02 2009-06-25 Duramed Pharmaceuticals, Inc. Methods of Step-Down Hormone Treatment
US7772219B2 (en) * 2003-05-02 2010-08-10 Teva Women's Health, Inc. Methods of hormonal treatment utilizing extended cycle contraceptive regimens
US20040222123A1 (en) * 2003-05-06 2004-11-11 Barr Laboratories, Inc. Kit for pharmaceuticals
CA2771944A1 (en) 2003-07-16 2005-01-27 Teva Women's Health, Inc. Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
ATE474795T1 (de) 2003-09-04 2010-08-15 Pharmadesign Inc Behälter mit tablettenaufnahmehülsen zur lagerung und ausgabe von tabletten
EP1535618A1 (en) 2003-11-26 2005-06-01 Schering Aktiengesellschaft Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions
EP1735056B1 (en) 2004-03-19 2012-10-24 Warner Chilcott Company, LLC Extended cycle multiphasic oral contraceptive method
US20050250746A1 (en) * 2004-05-06 2005-11-10 Matthew Iammatteo Premenstrual dysphoric disorder medication
WO2005117898A1 (en) * 2004-05-26 2005-12-15 Wyeth Compositions and methods for treatment of premenstrual dysphoric disorder
US20080280861A1 (en) * 2004-09-27 2008-11-13 Pantarhei Bioscience B.V. Method of Female Contraception and a Kit For Use Therein
US20070111975A1 (en) * 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
EP2392332A1 (en) * 2004-10-07 2011-12-07 Teva Women's Health, Inc. Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
US20060241092A1 (en) * 2005-04-15 2006-10-26 Anderson Freedolph D Contraceptive regimens for lower-weight women
TW200726473A (en) * 2005-06-28 2007-07-16 Wyeth Corp Compositions and methods for treatment of cycle-related symptoms
DE102005056527A1 (de) * 2005-11-25 2007-07-12 Grünenthal GmbH Verwendung einer Kombination aus Ethinylestradiol und Chlormadinonacetat zur Herstellung eines Arzneimittels
DE102006003508A1 (de) * 2006-01-24 2007-07-26 Grünenthal GmbH Arzneimittel umfassend eine Hormonkombination
MX2008011074A (es) * 2006-03-02 2008-09-10 Warner Chilcott Co Inc Metodo anticonceptivo oral multifasico de ciclo prolongado.
US8399432B2 (en) * 2009-10-27 2013-03-19 Lipogen Ltd. Compositions and methods of treatment for alleviating premenstrual syndrome symptoms
US9517328B2 (en) * 2013-06-19 2016-12-13 Kashiv Pharma, Llc Medicament applicator
AU2017330348B2 (en) 2016-09-22 2023-09-07 Alan B. Cash Method to alleviate the symptoms of PMS
US11679114B2 (en) 2021-07-26 2023-06-20 Navad Life Sciences Pte Progestogen-only oral contraception

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US575690A (en) * 1897-01-26 Match-safe
US428051A (en) * 1890-05-13 Wood-working machine
US3568828A (en) 1967-03-01 1971-03-09 Squibb & Sons Inc Modified sequential oral contraceptive
US4171358A (en) 1974-04-19 1979-10-16 Eli Lilly And Company Novel contraceptive method
US4145416A (en) * 1976-06-23 1979-03-20 Schering, A.G. Novel agents and novel methods for treatment of climacteric disturbances
US4292315A (en) * 1977-12-30 1981-09-29 Nichols Vorys Follicular phase estrogen or progestin with physiologic estrogen/progestin luteal phase replacement drug delivery system
US4215691A (en) * 1978-10-11 1980-08-05 Alza Corporation Vaginal contraceptive system made from block copolymer
US4291014A (en) 1979-01-11 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing estradiol diacetate
US4438139A (en) * 1979-08-14 1984-03-20 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing estrogens
US4390531A (en) 1981-08-10 1983-06-28 Syntex Pharmaceuticals International Ltd. Method of contraception using peak progestogen dosage
USRE35724E (en) * 1982-04-28 1998-02-03 Bio-Technology General Corp. Contraception system and method
US4921843A (en) * 1988-10-20 1990-05-01 Pasquale Samuel A Contraception system and method
US4826831A (en) * 1983-08-05 1989-05-02 Pre Jay Holdings Limited Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
US4616006A (en) 1983-09-26 1986-10-07 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4544554A (en) 1983-09-26 1985-10-01 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4628051A (en) 1983-09-26 1986-12-09 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4530839A (en) 1983-09-26 1985-07-23 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4736849A (en) 1983-12-19 1988-04-12 Leonard Walter G Calendar-oriented pill dispenser
US4534468A (en) 1983-12-19 1985-08-13 Nuckols Walter S Calendar-oriented pill dispenser
JPS60174716A (ja) 1984-02-21 1985-09-09 Yamanouchi Pharmaceut Co Ltd パツチ剤
US4962098A (en) 1987-06-15 1990-10-09 Warner-Lambert Company Graduated estrogen contraceptive
US5010070A (en) 1987-06-15 1991-04-23 Warner-Lambert Company Graduated estrogen contraceptive
US4752478A (en) 1984-12-17 1988-06-21 Merck & Co., Inc. Transdermal system for timolol
US5208225A (en) * 1986-02-27 1993-05-04 Warner-Lambert Company Compositions containing fixed combinations
US4762717A (en) 1986-03-21 1988-08-09 The General Hospital Corporation Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use as a contraceptive
IE61236B1 (en) 1986-07-15 1994-10-19 American Home Prod Combination dosage form for pre-menopausal women
US5276022A (en) * 1987-09-24 1994-01-04 Jencap Research Ltd. Hormone preparation and method
US5256421A (en) * 1987-09-24 1993-10-26 Jencap Research Ltd. Hormone preparation and method
US5108995A (en) * 1987-09-24 1992-04-28 Jencap Research Ltd. Hormone preparation and method
US4971998A (en) * 1987-10-22 1990-11-20 Massachusetts Institute Of Technology Methods for treating the premenstrual or late luteal phase syndrome
EP0386117B1 (en) * 1987-10-22 1999-01-07 Massachusetts Institute Of Technology Treating premenstrual or late luteal phase syndrome
US5043331A (en) * 1989-06-15 1991-08-27 Orion-Yhtyma Oy Treatment of postmenopausal disorders
US5098714A (en) 1989-11-16 1992-03-24 Alza Corporation Osmotic, oral dosage form for fertility control
NZ240319A (en) * 1990-10-25 1994-10-26 Schering Corp Preparation of florfenicol and its analogs from oxazoline derivatives
IE71203B1 (en) 1990-12-13 1997-02-12 Akzo Nv Low estrogen oral contraceptives
DE4104385C1 (pt) * 1991-02-09 1992-08-13 Marika Dr.Med. 6509 Framersheim De Ehrlich
US5211952A (en) * 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
ZA924811B (en) * 1991-06-28 1993-12-29 Endorecherche Inc Controlled release systems and low dose androgens
MX9301121A (es) * 1992-03-02 1993-09-01 Schering Ag Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina.
DE4224534A1 (de) 1992-07-24 1994-01-27 Marika Dr Med Ehrlich Ovulationshemmendes Mittel zur hormonalen Kontrazeption
NL9301562A (nl) * 1993-09-09 1995-04-03 Saturnus Ag Preparaat voor substitutietherapie.
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
DE4344405C2 (de) * 1993-12-24 1995-12-07 Marika Dr Med Ehrlich Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption
DE4411585A1 (de) * 1994-03-30 1995-10-05 Schering Ag Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption
US5552394A (en) * 1994-07-22 1996-09-03 The Medical College Of Hampton Roads Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy
DE4429374C1 (de) * 1994-08-12 1996-02-01 Jenapharm Gmbh Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente
DE19513662A1 (de) * 1995-04-08 1996-10-10 Schering Ag Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption
DE19525017A1 (de) * 1995-06-28 1997-01-02 Schering Ag Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption
FR2737411B1 (fr) 1995-08-01 1997-10-17 Theramex Nouveaux medicaments hormonaux et leur utilisation pour la correction des carences estrogeniques
DE19531936A1 (de) 1995-08-17 1997-02-20 Schering Ag Kombinationspräparat zur Kontrazeption, Kits diese enthaltend und eine Methode diese verwendend
DE19540253C2 (de) 1995-10-28 1998-06-04 Jenapharm Gmbh Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene
US5747480A (en) * 1996-05-08 1998-05-05 American Home Products Corporation Oral contraceptive
US6139873A (en) 1996-07-10 2000-10-31 Cedars-Sinai Medical Center Combined pharmaceutical estrogen-androgen-progestin
US6479475B1 (en) 1996-07-26 2002-11-12 Wyeth Oral contraceptive
AU3961697A (en) * 1996-07-26 1998-02-20 American Home Products Corporation Oral contraceptive
WO1998004246A2 (en) 1996-07-26 1998-02-05 American Home Prod Triphasic contraceptive method and kit comprising a combination of a progestin and estrogen
US5858405A (en) * 1996-07-26 1999-01-12 American Home Products Corporation Oral contraceptive
WO1998004267A1 (en) 1996-07-26 1998-02-05 American Home Products Corporation Progestin/estrogen oral contraceptive
US6511970B1 (en) * 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
US6028064A (en) * 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
US6765002B2 (en) 2000-03-21 2004-07-20 Gustavo Rodriguez Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
DE19705229C2 (de) * 1997-02-12 1999-04-15 Hesch Rolf Dieter Prof Dr Med Verwendung von drei Hormonkomponenten zur hormonalen Kontrazeption zur Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
JP2001518103A (ja) * 1997-03-20 2001-10-09 ビーエーエスエフ アクチェンゲゼルシャフト 置換２−ベンジル（ベンゾイル）ピリジン
US5898032A (en) * 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
US6251956B1 (en) * 1998-08-20 2001-06-26 Ortho Pharmaceutical Corporation Combination progestin oral contraceptive regimen
DE19739916C2 (de) * 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
AU759925B2 (en) 1997-09-12 2003-05-01 Wyeth Oral contraceptive preparation having a first phase comprising progestin/estrogen and a second phase comprising progestin
US6306914B1 (en) * 1997-10-21 2001-10-23 Columbia Laboratories, Inc. Progestin therapy for maintaining amenorrhea
US6265393B1 (en) * 1998-08-07 2001-07-24 Heinrichs William Leroy Prevention of endometriosis signs or symptons
US6214815B1 (en) 1998-12-23 2001-04-10 Ortho-Mcneil Pharmaceuticals, Inc. Triphasic oral contraceptive
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
AU2001273074A1 (en) * 2000-07-06 2002-01-21 Wyeth Combinations of ssri and estrogenic agents
AU2002309919B2 (en) 2001-05-16 2008-04-10 Barr Laboratories, Inc. Treatment of conditions relating to hormone deficiencies by administration of progestins
US20030018018A1 (en) * 2001-07-10 2003-01-23 Medical College Of Hampton Roads Ultra low dose oral contraceptives with sustained efficacy and induced amenorrhea
PT1453521E (pt) * 2001-12-05 2013-10-08 Teva Womens Health Inc Contracetivos orais para prevenir a gravidez e diminuir a sintomatologia pré-menstrual
ES2197801B1 (es) * 2002-03-05 2005-03-16 Ferrer Internacional,S.A Procedimiento de obtencion de la 3-(2-(4-(6-fluoro-benzo(d)isoxazol-3-il) piperidin-1-il)-etil)-2-metil-6,7,8,9-tetrahidro-4h-pirido-(1,2-a ) pirimidin-4-ona.
US20040142914A1 (en) * 2002-03-11 2004-07-22 Friedman Andrew Joseph Extended transdermal contraceptive regimens
US20030219471A1 (en) 2002-03-11 2003-11-27 Caubel Patrick Michel Extended cycle estrogen and sulfatase inhibiting progestogen contraceptive regimens
ES2269999T3 (es) * 2002-03-11 2007-04-01 Janssen Pharmaceutica N.V. Terapia hormonal sustitutiva que inhibe progestageno sulfatasa continua.
WO2003084547A1 (en) * 2002-04-03 2003-10-16 Barr Laboratories, Inc. Step-down estrogen therapy
US7772219B2 (en) 2003-05-02 2010-08-10 Teva Women's Health, Inc. Methods of hormonal treatment utilizing extended cycle contraceptive regimens
US20040251301A1 (en) 2003-05-05 2004-12-16 Niemann Amy C. Device for calculating anticipated days for menstruation
US20040222123A1 (en) 2003-05-06 2004-11-11 Barr Laboratories, Inc. Kit for pharmaceuticals
CA2771944A1 (en) 2003-07-16 2005-01-27 Teva Women's Health, Inc. Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
ATE474795T1 (de) 2003-09-04 2010-08-15 Pharmadesign Inc Behälter mit tablettenaufnahmehülsen zur lagerung und ausgabe von tabletten
CN1863537A (zh) 2003-10-01 2006-11-15 詹森药业有限公司 延长的三阶段避孕法
EP2392332A1 (en) * 2004-10-07 2011-12-07 Teva Women's Health, Inc. Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
US20070111975A1 (en) 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
US20090247493A1 (en) 2006-01-27 2009-10-01 Duramed Pharmaceuticals, Inc. Regimens for Treatment of Conditions Related to Estrogen Deficiency

Also Published As

Publication number Publication date
CA2468748C (en) 2010-01-26
FR15C0050I2 (fr) 2018-05-11
HK1076716A1 (en) 2006-01-27
FR15C0050I1 (fr) 2015-08-28
CN100581550C (zh) 2010-01-20
US20100298279A1 (en) 2010-11-25
MXPA04005445A (es) 2005-03-23
HUP0402651A2 (hu) 2005-04-28
CN101757628A (zh) 2010-06-30
LU93156I2 (fr) 2016-09-20
HU230759B1 (hu) 2018-03-28
JP2012107052A (ja) 2012-06-07
JP2005516913A (ja) 2005-06-09
BRPI0214716B8 (pt) 2021-05-25
IL207561A0 (en) 2011-07-31
US8680084B2 (en) 2014-03-25
EP2305230B1 (en) 2015-11-04
US20120322777A1 (en) 2012-12-20
US7615545B2 (en) 2009-11-10
PL213122B1 (pl) 2013-01-31
WO2003049744A1 (en) 2003-06-19
PL370135A1 (en) 2005-05-16
HUP0402651A3 (en) 2009-01-28
NZ533242A (en) 2007-11-30
CA2655959C (en) 2013-05-14
EP2305229A1 (en) 2011-04-06
IL162182A (en) 2012-02-29
ES2428118T3 (es) 2013-11-06
US8338396B2 (en) 2012-12-25
AU2008237614A1 (en) 2008-11-27
US20080064670A1 (en) 2008-03-13
AU2002348272B2 (en) 2008-07-31
HK1154485A1 (zh) 2012-04-27
SI1453521T1 (sl) 2013-11-29
US20030139381A1 (en) 2003-07-24
ES2561491T3 (es) 2016-02-26
AU2008237614B2 (en) 2011-04-21
CA2655959A1 (en) 2003-06-19
BG108736A (bg) 2005-03-31
RU2004121155A (ru) 2005-05-27
EP1453521B1 (en) 2013-09-04
IL162182A0 (en) 2005-11-20
US7320969B2 (en) 2008-01-22
AU2002348272A1 (en) 2003-06-23
CN1599614A (zh) 2005-03-23
EP1453521A1 (en) 2004-09-08
NZ591627A (en) 2012-09-28
BRPI0214716B1 (pt) 2018-10-02
RU2351339C2 (ru) 2009-04-10
HUS1800033I1 (hu) 2018-08-28
NZ570295A (en) 2011-05-27
NZ555299A (en) 2008-10-31
CA2468748A1 (en) 2003-06-19
JP2010180236A (ja) 2010-08-19
EP2305230A1 (en) 2011-04-06
WO2003049744B1 (en) 2003-08-28
US20080132473A1 (en) 2008-06-05
PT1453521E (pt) 2013-10-08
ZA200404249B (en) 2005-08-31
DK1453521T3 (da) 2013-10-07
US7858605B2 (en) 2010-12-28

Similar Documents

Publication Publication Date Title
BR0214716A (pt) Contraceptivos para prevenção de gravidez e diminuição de sintomatologia pré-menstrual
BR0200155A (pt) Tratamento combinado para depressão
BR0016652A (pt) Métodos para inibir angiopatia amilóide cerebral, para tratar um estado de doença caracterizado por angiopatia amilóide cerebral em um indivìduo, e para diagnosticar angiopatia amilóide cerebral em um indivìduo
BR0212019A (pt) Formas de dosagem, métodos para o tratamento da dor, métodos de preparação de uma forma de dosagem e métodos para impedir o abuso de uma forma de dosagem
BR0114410A (pt) Associação de um antagonista de receptor cb1 e de sibutramina, as composições farmacêuticas que os contêm e a respectiva utilização para o tratamento da obesidade
BR9912508A (pt) Métodos e composições transdérmicas para alìvio da dor
BR0213589A (pt) Formas de dosagens de liberação modificada
BR0212374A (pt) Oxintomodulina para a prevenção ou para o tratamento do excesso de peso
BR0013122A (pt) Ciclobenzaprina para tratamento de distúrbio de ansiedade generalizado e composições de ciclobenzaprina
BR0109966A (pt) Combinação de compostos orgânicos
ES2174920T3 (es) Producto de combinacion para la contracepcion que contiene agentes antagonistas de progesterona y un agente gestageno.
BR9814923A (pt) Método para tratamento de doença de alzheimer
BRPI0414876A (pt) compostos e composições farmcêuticas para prevenção de overdose ou abuso e respectivos usos
BR9911440A (pt) Composição para a prevenção e/ou tratamento de osteoporose e alterações devido à sìndrome de menopausa
BR0210056A (pt) composições e métodos para tratamento de hiperplasia
BR0113649A (pt) Processo para aumentar a testosterona e as relacionadas concentrações de esteróide em mulheres
BRPI0416700A (pt) métodos para tratar obesidade, para alcançar perda de peso desejável, para evitar ganho de peso indesejável, e para facilitar a perda de peso em um indivìduo não sofrendo de depressão, métodos de manutenção de um peso estável e de redução do peso corporal em um indivìduo, composição farmacêutica, e, kit
TR200101895T2 (tr) Cinsel rahatsızlıkların tedavisi.
BR0016707A (pt) Forma de dosagem de droga em camadas acionada por hidrogel
BR9909138A (pt) Combinação para o tratamento de dependência de álcool e drogas contendo um antagonista de opióide e um modulador de complexo receptor de nmda
BR0206639A (pt) Combinações de inibidor(es) da absorção do esterol com modificador(es) do sangue para o tratamento de condições vasculares
CO5150236A1 (es) Metodo para tratar asma inducida por el ejercicio inducida por el ejercicio
BR0100541A (pt) Suplemento de alimentação pró-energético baseado em nadh, octocosonol e vitamina e
BR9814711A (pt) Composições e processos para aumentar a concentração e/ou motilidade de espermatozóides em seres humanos
BR0306306A (pt) Composição contendo extrato de matricária e uso desta

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: DURAMED PHARMACEUTICALS, INC. (US)

Free format text: TRANSFERIDO DE: BARR LABORATORIES, INC.

B25G Requested change of headquarter approved

Owner name: DURAMED PHARMACEUTICALS, INC. (US)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 018080073262/SP DE 27/11/2008.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: TEVA WOMEN'S HEALTH, INC. (US)

Free format text: NOME ALTERADO DE: DURAMED PHARMACEUTICALS, INC.

B25G Requested change of headquarter approved

Owner name: TEVA WOMEN'S HEALTH, INC. (US)

Free format text: ENDERECO ALTERADO CONFORME SOLICITADO NA PETICAO NO 018110020180/SP DE 30/05/2011.

B15V Prolongation of time limit allowed

Free format text: RECONHECIDO OBSTACULO ADMINSTRATIVO E DEVOLVIDO O PRAZO DE 33 DIAS, NOS TERMOS DO ARTIGO 221 2O DA LPI E RESOLUCAO 116/2004 .

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/10/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/12/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 19A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2647 DE 28-09-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.